Assoc ProfessorFiona Freeman
Associate Professor
School of Mechanical and Materials Engineering
Orcid identifier0000-0002-6662-4356 (opens in a new tab)
- Associate ProfessorSchool of Mechanical and Materials Engineering
- 01 716 1831
- University College Dublin, School of Mechanical and Materials Engineering, Engineering Building Belfield Dublin 4
BIO
Dr. Fiona Freeman is an Associate Professor and Ad Astra Fellow in the School of Mechanical and Materials Engineering at University College Dublin (UCD). She graduated in Biomedical Engineering in 2011 and earned her PhD from the University of Galway in 2016, focusing on developing new strategies for bone tissue regeneration. Afterward, Dr. Freeman was awarded two prestigious postdoctoral fellowships: the Government of Ireland IRC Postdoctoral Research Fellowship and the Marie Skłodowska-Curie Global Fellowship. These fellowships provided her with opportunities to work as a postdoctoral researcher in renowned labs at the Massachusetts Institute of Technology (MIT), Brigham and Women's Hospital, Johns Hopkins University, and Trinity College Dublin.
Dr. Freeman leads a multidisciplinary research group investigating the use of innovative biomedical engineering techniques to better understand and develop novel therapeutics to treat paediatric bone cancer, Osteosarcoma. Her group is pursuing two different approaches to osteosarcoma. The first involves developing patient-specific models of osteosarcoma for drug development. Accelerating cures for those patients with poor outcomes remains a challenge, and this is in part due to the fact that osteosarcoma is a relatively rare disease. Therefore, recruiting enough eligible participants to conduct clinical trials is a difficult endeavour. These patient-specific models can act as a potential screening method for new cancer treatments, as they provide the flexibility to understand how organs might respond to potential new treatments before conducting full clinical trials.
The second avenue Dr. Freeman's lab is exploring is the development of novel therapeutics that can be used as an add-on to traditional chemotherapy to enhance the therapeutic potential of the treatment. Dr. Freeman’s research has identified a novel microRNA, miR-29b, as a potential therapeutic target for osteosarcoma. In particular, she is focused on designing smart delivery vehicles that can transport the treatment directly to cancer cells or the patient's own immune cells to enhance the patient's ability to attack the tumour itself.
Fiona is a current Ad Astra Fellow, a Conway Fellow, a European Research Council Starter Grant awardee, a funded investigator in the SFI Research Centre for Advanced Materials and Bioengineering Research, and a PI within UCD Centre for Biomedical Engineering and Trinity Centre for Bioengineering.
Dr. Freeman leads a multidisciplinary research group investigating the use of innovative biomedical engineering techniques to better understand and develop novel therapeutics to treat paediatric bone cancer, Osteosarcoma. Her group is pursuing two different approaches to osteosarcoma. The first involves developing patient-specific models of osteosarcoma for drug development. Accelerating cures for those patients with poor outcomes remains a challenge, and this is in part due to the fact that osteosarcoma is a relatively rare disease. Therefore, recruiting enough eligible participants to conduct clinical trials is a difficult endeavour. These patient-specific models can act as a potential screening method for new cancer treatments, as they provide the flexibility to understand how organs might respond to potential new treatments before conducting full clinical trials.
The second avenue Dr. Freeman's lab is exploring is the development of novel therapeutics that can be used as an add-on to traditional chemotherapy to enhance the therapeutic potential of the treatment. Dr. Freeman’s research has identified a novel microRNA, miR-29b, as a potential therapeutic target for osteosarcoma. In particular, she is focused on designing smart delivery vehicles that can transport the treatment directly to cancer cells or the patient's own immune cells to enhance the patient's ability to attack the tumour itself.
Fiona is a current Ad Astra Fellow, a Conway Fellow, a European Research Council Starter Grant awardee, a funded investigator in the SFI Research Centre for Advanced Materials and Bioengineering Research, and a PI within UCD Centre for Biomedical Engineering and Trinity Centre for Bioengineering.
UNIVERSITY COLLEGE DUBLIN APPOINTMENTS
- Associate ProfessorUniversity College Dublin, School of Mechanical and Materials Engineering, Ireland4 Apr 2024
- Ad Astra FellowUniversity College Dublin, School of Mechanical and Materials Engineering, Dublin, Ireland1 Sep 2022
- Junior Conway FellowUCD Conway Institute, Dublin, Ireland19 Oct 2022
- Assistant ProfessorUniversity College Dublin, School of Mechanical and Materials Engineering, Dublin, Ireland1 Sep 2022 - 3 Apr 2024
ACADEMIC POSITIONS
- Marie Skłodowska-Curie Global FellowBrigham and Women's Hospital, Boston, United States1 Jul 2019 - 30 Jun 2022
- Marie Skłodowska-Curie Global FellowMassachusetts Institute of Technology, Cambridge, United States1 Jul 2019 - 30 Jun 2022
- Postdoctoral FellowTrinity College Dublin, Mechanical, Manufacturing & Biomedical Engineering, Dublin, Ireland1 Feb 2016 - 31 Aug 2022
DEGREES
- BEngNUI Galway IRL
- CertificateMassachusetts Inst of Tech
- PhDNUI Galway IRL
CERTIFICATIONS
- Kaufman Teaching Certificate ProgramMassachusetts Institute of Technology, Cambridge, United States2021